Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00621569 · ClinicalTrials.gov registry record · NA
ADAPT-Altering Diet for African American Populations to Treat Hypertension
A NA study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- NA
- Development phase
- 122
- Enrollment target
NCT00621569: Completed NA study, sponsored by University of Alabama at Birmingham.
NCT00621569 is a NA study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 122 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00621569, a NA study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- NA
- Development phase
- 122 participants
- Enrollment target
Study Summary
The purpose of the study is to develop a culturally appropriate DASH intervention and test the effectiveness of the intervention lower blood pressure in a group of African American participants at risk for developing hypertension (pre-hypertension) and those with mild hypertension (stage I).
Interventions
- BEHAVIORAL Dietary Approaches to Stop Hypertension-The DASH diet
- BEHAVIORAL Intervention with no dietary component - information regarding useful life skills
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2005-01 |
| Est. Completion | 2011-12 |
| Phase | NA |
What the finished NCT00621569 record still lists
NCT00621569 is an interventional study that assigns participants to a tested intervention. The registered 122 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 2 interventions - of which Dietary Approaches to Stop Hypertension-The DASH diet is the first listed.
NCT00621569 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00621569 about?
NCT00621569 is a clinical study titled "ADAPT-Altering Diet for African American Populations to Treat Hypertension". The purpose of the study is to develop a culturally appropriate DASH intervention and test the effectiveness of the intervention lower blood pressure in a group of African American participants at risk for developing hypertension (pre-hypertension) and those with mild hypertension (stage I).
What is the current status of trial NCT00621569?
This trial is currently completed. It is a NA study. The enrollment target is 122 participants. The study started on 2005-01. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00621569?
The interventions under investigation include: Dietary Approaches to Stop Hypertension-The DASH diet (BEHAVIORAL), Intervention with no dietary component - information regarding useful life skills (BEHAVIORAL).
Who is sponsoring clinical trial NCT00621569?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00621569's enrollment target sits among peer trials
122 762nd of 2000 higher than 1,239 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03363373 · 122 participants · Phase 2
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
- NCT03463954 · 122 participants · NA
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
- NCT04503265 · 122 participants · Phase 1
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- NCT04700527 · 122 participants · Phase 1
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia